Collplant Ltd of Rehovot at MEDICA 2019 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

Collplant Ltd

4, Oppenheimer St., 7670104 Rehovot
Telephone +972 73 232561
Fax +972 73 23256

This company is co-exhibitor of
Israel Export & International Cooperation Institute

Hall map

MEDICA 2019 hall map (Hall 16): stand M25

Fairground map

MEDICA 2019 fairground map: Hall 16


Inbal Carmel



Our range of products

Product categories

  • 05  Commodities and Consumer Goods
  • 05.15  Wound care equipment
  • 05.15.07  Wound covering / skin substitutes

Wound covering / skin substitutes

Our products

Product category: Wound covering / skin substitutes

3D Bioprinting

rhCollagen BioInk for 3D Bioprinting of Tissues and Organs
Recently, 3D bioprinting has been gaining momentum in many medicinal applications to address the need for complex scaffolds, tissues and organs suitable for transplantation and tissue modeling. For that purpose, CollPlant’s rhCollagen was modified chemically to adapt the biological molecules for printing, such that the BioInk maintains controlled fluidity during printing, and cures to form hydrogel when irradiated by light ranging from UV to visible light. The unique viscosity and shear thinning properties of the modified rhCollagen allow the flexibility to easily formulate BioInks for different printing technologies including extrusion, ink-jet, Laser Induced Forward Transfer (LIFT) and Stereolithography. The control of chemical modification in combination with illumination energy allows tight control on the physical properties of the resulting scaffolds to match natural tissues properties, from stiff cartilage to soft adipose. BioInks formulated from rhCollagen were evaluated with all major printing technologies and exhibited the required physical properties as well as excellent support for cells including a series of primary and differentiated human cells. In conclusion, rhCollagen BioInk formulations provide a superior solution for 3D bioprinting of tissues and organs.

  • CollPlant’s rhCollagen-based BioInk key attributes:
  • Controlled rheological properties (e.g. viscosity)
  • Shear thinning properties – compatible with inkjet technology
  • Biocompatibility: Supports cells viability and proliferation (e.g. Endothelial cells, Fibroblasts, Keratinocytes, MSCs)
  • Non-immunogenic
  • Excellent biosafety profile
  • Supplied at different formulations (e.g. concentration up to 20mg/ml, pH acidic or neutral)
  • Convenient handling at broad range of temperatures and pH (e.g. maintains liquid properties at RT and above – no gelation)
  • Compatible with different photoinitiators to cover the spectrum of 280-500nm

More Less

Product category: Wound covering / skin substitutes


Chronic, painful tendon and ligament disorders such as tendinopathy are frequent in both athletic and less active or inactive individuals. Patients are commonly referred to general and sports medicine practitioners, but the tools for treatment are limited and too often not efficient. One of the evolving treatment options for tendinopathy includes the use of PRP (Platelet Rich Plasma, a concentrated blood plasma that contains high levels of platelets) extracted from the patients’ blood, which serves as a storage for healing-promoting growth factors. However, PRP usually displays poor retention of the platelets at the injury site and their fast dissipation may limit the effect of the growth factors.

Vergenix™STR is a soft tissue repair matrix that was designed for mixing with PRP to form a scaffold with delayed degradation and enhanced retention to the injury site, in order to enable a localized, prolonged therapeutic effect.

Vergenix™STR is intended for treatment of tendinopathy.

VergenixSTR is distributed in Europe by Arthrex, and is marketed together with the Arthrex ACP® kit, under the brand ACP® Tendo. More information regarding product procurement can be found in Arthrex’s website:

More Less

Product category: Wound covering / skin substitutes


Healing of chronic diabetic and venous wounds, pressure ulcers, traumatic injuries and surgical wounds is a major challenge faced by so many patients and their physicians. To heal them, the body needs to generate new tissue through utilization of it’s own natural resources which are often lacking. Now there is a solution: Vergenix™FG .

Vergenix™FG is an advanced wound care product based on our rhCollagen technology indicated for the management of chronic and acute wounds.

Vergenix™FG is unique. It is a flowable wound-filler of real human collagen derived from plants using a proprietary process. Vergenix™FG enhances the quality and closure speed of chronic and acute wounds.

More Less

About us

Company details

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant’s proprietary plant based genetic engineering technology.

Our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. Our flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs, and our unique Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds.

Our VisionWe strive to be the leading company in the field of regenerative medicine by delivering innovative products that offer the best treatment options to patients and their physicians.

More Less